Silk Road Medical Inc. (SILK) Tops Q1 EPS by 8c, Revenues Beat; Raises FY21 Revenue Guidance

Silk Road Medical Inc. (NASDAQ: SILK) reported Q1 EPS of ($0.31), $0.08 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $21.3 million.

“Our first quarter results were characterized by meaningful progress on several commercial and operational initiatives and strong financial performance,” said Erica Rogers, President and Chief Executive Officer of Silk Road Medical. “Procedure trends are improving, and we are working closely with our trained physicians to drive adoption of TCAR as the environment normalizes. Simultaneously, we are driving forward development efforts aimed at new indications, therapies, and market opportunities.”

GUIDANCE:

Silk Road Medical Inc. sees FY2021 revenue of $103-108 million, versus the consensus of $105.46 million.

• Silk Road Medical projects revenue for the full year 2021 to range from $103 million to $108 million. This compares to previous revenue guidance of $102 million to $108 million.

For earnings history and earnings-related data on Silk Road Medical Inc. (SILK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Z Squared outlines AI power strategy and Paradox Data acquisition